Merck KGaA sheds light on failed portion of phase 2 lupus trial, keeps sights on regulators
Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary endpoint wins as proof that enpatoran still deserves a shot at seeking approval.
